Sign In
Buy TAK
$15.03
-0.150 (-0.99%)
At Close: Jun 03, 2026
Takeda's dengue vaccine gets WHO group's recommendation
05:36pm, Tuesday, 03'rd Oct 2023
American depositary receipts of Takeda Pharmaceutical Co. 4502, -1.79% TAK, -2.16% rose more than 1% in the extended session Tuesday after the Japan-based company said its dengue vaccine got the recom
Takeda announces voluntary withdrawal of lung cancer therapy
05:13pm, Monday, 02'nd Oct 2023
Takeda Pharmaceutical said on Monday it would be working with the U.S. health regulator towards a voluntary withdrawal of its lung cancer therapy in the country, after it failed to meet the main goal
Generic drugmakers start shipping copies of Takeda's ADHD drug Vyvanse
03:49pm, Thursday, 31'st Aug 2023
Drugmakers have begun shipping copycat versions of Takeda Pharmaceutical's drug Vyvanse, which is expected to offset the ongoing shortage of the ADHD medicine in the United States.
ImmunoGen stock jumps after licensing deal with Japan's Takeda Pharmaceutical
06:50am, Monday, 28'th Aug 2023
Shares of ImmunoGen Inc. IMGN, +1.45% jumped 1.7% in premarket trading Monday, after the Massachusetts-based drug maker announced a collaboration with Takeda Pharmaceutical Co. Ltd. TAK, +0.59% 4502,
Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now?
11:16am, Friday, 25'th Aug 2023
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Better High-Yield Dividend Stock: Takeda Pharmaceutical vs. Viatris
05:00pm, Thursday, 24'th Aug 2023
One of these high-yield pharma stocks stands out as a better buy right now.
2 Ultra-Cheap High-Yield Dividend Stocks to Buy Now
02:22pm, Wednesday, 23'rd Aug 2023
High-yield dividend stocks can be great additions to a long-term-oriented portfolio. Takeda Pharmaceutical and AT&T screen as two of the most attractive buys in the high-yield space right now.
Takeda says it has 40 clinical-stage medicines in the pipeline
12:46am, Friday, 28'th Jul 2023
Christophe Weber, CEO of Takeda, says there are some setbacks in research and development, but most of those drugs should fuel the company's growth in the future.
Takeda withdraws US application for dengue vaccine candidate
11:32am, Tuesday, 11'th Jul 2023
Takeda Pharmaceutical Co said on Tuesday it was voluntarily withdrawing its application for its dengue vaccine candidate, following discussions with the U.S. health regulator.
Takeda: Upside Case Strengthening, Looking To 15x Earnings
02:47am, Wednesday, 21'st Jun 2023
Takeda Pharmaceutical's stock has appreciated 10% since December, with economic and fundamental catalysts supporting a buy rating. TAK has shown strong growth in revenue and operating capital as well
Takeda Pharmaceutical Company Limited (TAK) Q4 2022 Earnings Call Transcript
10:42pm, Thursday, 11'th May 2023
Takeda Pharmaceutical Company Limited (NYSE:TAK ) Q4 2022 Results Conference Call May 11, 2023 6:00 AM ET Company Participants Christopher O'Reilly - Global Head of IR & Global Finance Christophe Webe
Why Do We Keep Buying Takeda Pharmaceutical Shares
03:51am, Monday, 03'rd Apr 2023
Sales of Takhzyro amounted to 44.1 billion Japanese yen in the 3rd quarter of 2022, an increase of 42.7% from the previous year. Takeda Pharmaceutical's revenue was $8,354 million in Q3 2022, showing
Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?
11:23am, Thursday, 30'th Mar 2023
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Price Growth & Yield: For That Magical Combo, Leave the U.S.
12:01pm, Tuesday, 21'st Mar 2023
It's not often you find one stock with sustained price growth and solid dividend yield, but three foreign stocks, Takeda Pharmaceutical Co., Ltd. (NYSE: TAK), United Microelectronics Corp. (NYSE: UMC)
Big Stocks Making New Highs Despite Everything
02:50pm, Saturday, 18'th Mar 2023
Interest rates may be headed higher and regional banks may be in trouble but that hasn't stopped just a few stocks from hitting new highs.
